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Background: To identify dose-volume parameters predictive for severity of acute esophagitis (CTC > grade 2) in
locally-advanced non small-cell lung cancer (LA-NSCLC) patients treated with neoadjuvant concurrent
hyperfractionated-accelerated chemoradiotherapy (HA-CRT) a retrospective analysis was performed. 88 patients
were treated with HA-CRT followed by radical surgery. Predictive power of absolute oesophageal length, absolute
and relative oesophageal volume included in the 95%-isodose, patient- and tumor-related factors for severity of
acute esophagitis was assessed.
Findings: A total of 82 patients (93%) developed radiation-induced acute esophagitis. Grade 1 was documented in
1 (1%), grade 2 in 55 (67%), grade 3 in 23 (28%) and grade 4 in 3 (4%) patients, respectively. Absolute oesophageal
volume included in the 95%-isodose (42.8 Gy) achieved 13.5 cm3 (range: 3 – 29 cm3). Of the tested variables in
univariate analysis, absolute oesophageal volume included in the 95%-Isodose was found to be the only significant
variable (p = 0.03) predicting severe acute esophagitis (CTC > grade 2). For this volume a gradation scale of the
likelihood of severity was built.
Conclusion: Increase of absolute oesophageal volume included in the 95%-isodose correlates with severity of acute
esophagitis in LA-NSCLC patients treated with neo-adjuvant concurrent HA-CRT.
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Concurrent chemoradiotherapy (CRT) is the most re-
levant treatment option for inoperable LA-NSCLC. Meta-
analysis documented that definitive concurrent CRT is
associated with a significant prolongation of overall survival
compared to thoracic irradiation (TRT) alone [1]. However,
local control is still poor. Thus, new treatment protocols
aiming to increase local control are urgently needed. In-
creasing the dose density via hyper-fractionated-accelerated
radiation protocols represents one of the known options in* Correspondence: farkhad.manapov@med.uni-muenchen.de
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reproduction in any medium, provided the ororder to increase local control rates. Saunders et al. were
the first who documented a superiority of HA-radiotherapy
over conventional treatment regarding local relapse and
survival in NSCLC [2]. Similar results were reported for
limited-disease small-cell lung cancer treated with CRT [3].
RTOG 9410 phase III randomised trial for LA-NSCLC
which compared three different definitive CRT regimens
has reported that there were significantly fewer patients
with disease progression within the radiation field when
treated with concurrent HA-CRT [4].
An even more intense treatment in implemented when
a concurrent application of HA-TRT and chemotherapy is
followed by radical resection. At least two single-centre
trials have applied such a protocol and demonstrated upal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Likelihood of acute severe acute esophageal reaction
(>CTC grade 2) depends on the absolute esophageal volume
within 95%-Isodose (>42.8 Gy). The original binary data and the
resulting binary logistic regression line including the 95% confidence
limits (dashed lines) are displayed. Blue symbols and numbers
indicate events and number of events at the respective volume.
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improved long-term survival [5-7]. A multicentre rando-
mised phase III trial investigating this tri-modality concept
is still ongoing (EsPaTü) [8].
As trade-off, any dose escalation and treatment in-
tensification of TRT generally results in higher toxicity.
Besides pneumonitis, acute esophagitis is a highly im-
portant adverse effect and represents a dose-limiting
toxicity [9]. Therefore, the identification of predictive
factors for severe radiation-induced acute esophagitis is
of high clinical relevance. Most data concerning this
clinical problem reflect the situation in patients treated
with conventional TRT and it has to be questioned in
how far these data can be applied to HA-CRT. To define
relevant parameters in patients with hyper-fractionated
tri-modality concepts the impact of several dose-volume
parameters, patient- and tumor-related factors on the
severity of acute oesophageal reaction in patients with
LA-NSCLC were analysed.
Findings
All 88 patients (median age 55 years for women and
58 years for men) have participated in a prospective
phase II trial [5,7], were diagnosed with initially inope-
rable histologically proven LA-NSCLC and treated with
neoadjuvant HA-CRT followed by radical surgery when-
ever possible. All patients had a performance score (PS)
WHO 1–2. LA-NSCLC was defined as a disease corre-
sponding to Stage III A(2)-B after completion of initial
staging. All patients provided written informed consent.
Patients received four cycles of induction chemothe-
rapy (weekly carboplatin dosed at AUC 2 and paclitaxel
100 mg/m2) followed by 3 weeks of HA-CRT with
1.5 Gy twice a day up to 45 Gy combined with weekly
carboplatin AUC 2 and paclitaxel 50 mg/m2. Irradiation
was delivered with a linear accelerator using a multiple
field technique. 3D-CT treatment planning was per-
formed. Clinical target volume included primary tumor
with 1.0-cm safety margin and bilateral mediastinal nodes
from the jugulum to the level of the heart valves. Lower
mediastinum was included if nodal involvement was
suspected. For each patient oesophagus was delineated
from cricoid to gastro-oesophageal junction. Total abso-
lute oesophageal length and volume as well as length and
volume included in the 95%-isodose (42.8 Gy) were mea-
sured. Dose-volume histograms of oesophagus were pro-
vided for each individual patient. Symptom assessment of
acute esophagitis was performed weekly during the whole
course of HA-CRT. Severity of acute esophagitis was do-
cumented according to the “CTC v. 2”. Putative correla-
tions between absolute total oesophageal length, length
included in the 95%-isodose, absolute total oesophageal
volume, volume included in the 95%-Isodose and relative
oesophageal volume within the 95%-Isodose as well as ageat diagnosis, gender, initial T-stage, hematotoxicity and se-
verity of the acute oesophageal reaction were analysed
using the binary logistic regression module of the
“XLSTAT” software package. P-values and asymptotic
confidence limits were calculated based on the respective
co-variance matrices.
A total of 82 treated patients (93%) developed acute
esophagitis. Grade 1 acute esophagitis was detected in
1 (1%), grade 2 in 55 (67%), grade 3 in 23 (28%) and
grade 4 in 3 (4%) patients, respectively. All 82 patients
received symptomatic care. No esophagogastroduode-
noscopy was necessary during the whole course of treat-
ment. Dose-volumetric parameters of oesophagus were
correlated to the corresponding CTC-degree of the
radiation-induced acute esophagitis for each individual
patient. A similar analysis was done for patient- and
tumor-related factors.
On average, absolute total oesophageal length was
23.5 cm (range: 18 – 28 cm) and median length in-
cluded in the 95%-isodose (42.8 Gy) reached 13 cm
(range: 6 – 21 cm). Median total oesophageal volume was
24.5 cm3 (range: 9 – 43 cm3). Volume included in the
95%-isodose (42.8 Gy) achieved on average 13.5 cm3
(range: 3 – 29 cm3) and accounted for 51% (range: 18 –
89%) of total organ volume. Of the tested variables in the
univariate analysis, absolute oesophageal volume included
in the 95%-isodose was found to be the only significant
variable (p = 0.03) predicting severe acute esophagitis
(CTC > grade 2). No events of severe esophagitis were ob-
served at oesophageal volumes in the 95%-isodose below
10 ml. The original data and the resulting logistic regres-
sion are shown in Figure 1.
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factors and severity of radiation-induced acute esophagitis
was found.
Discussion
Neoadjuvant concurrent HA-CRT followed by radical
surgery in LA-NSCLC was shown to be a promising ap-
proach in single-centre studies and a multi-institutional
randomized phase III trial is actually ongoing [5-8].
In previous trials dose escalation and intensification of
TRT resulted in higher acute oesophageal toxicity which
was established as dose-limiting in patients treated with
different types of CRT. RTOG 9410 trial investigating
three different regimens reported a 45% rate of grade 3
acute esophagitis in the accelerated CRT arm [4]. Earlier,
Ball et al. have shown a significant increase of the rate of
severe acute esophagitis from 21% in the conventional
on 42% in accelerated CRT arm [10]. RTOG database
analysis on 528 LA-NSCLC patients revealed a strong
association of severe acute esophagitis with hyperfrac-
tionated CRT [11].
That is why a question arises again whether the severity
of acute esophagitis can be predicted on the basis of indi-
vidual dose-volumetric parameters. Patel et al. reported in
accelerated CRT that the critical parameter for develop-
ment of acute esophagitis was the oesophageal volume
treated with > 50 Gy [12]. A japanese study of conven-
tional CRT from Hirota and colleagues recommended that
the absolute oesophageal length and oesophageal volume
within 45 Gy-Isodose should amount less than 9.5 cm and
40%, respectively [13]. Importantly, both studies included
only a small number of patients. De Ruyck et al. have
found mean oesophageal dose, overall treatment time and
radiation technique as important parameters predicting
severe acute esophagitis [14].
Present study analysed highest number of patients
treated with neoadjuvant concurrent HA-CRT. Our ana-
lysis was built on the investigation of individual TRT
plans. Importantly, there were no differences in regard
to the PS, TNM stage and applied multimodality pro-
tocol within the treated population. A comparison of
calculated dose-volumetric parameters with carefully
assessed individual symptoms of acute esophagitis dur-
ing the HA-CRT was a basis for our investigation. An
absolute oesophageal volume received a dose of at least
42.8 Gy (within the 95%-isodose) was identified as a
dose-volumetric predictor for the severity of acute oeso-
phageal reaction in treated population. The increase of
this volume was strongly correlated with corresponding
increase of the CTC-grade and a gradation scale of the
likelihood of severity of acute esophagitis was created.
Results of our study gain special importance in the scope
of the ongoing multicentre randomized phase III trial.
Intensification of a neoadjuvant approach due to combi-nation of the chemo- and radiation therapy defines an
actual trend in the multimodality treatment of LA-
NSCLC. Prediction of the severity of acute esophagitis
based on individual dose-volumetric parameters help to
complete overall treatment without interruption. Our
gradation scale built a tool for further optimization of
radiation therapy treatment planning in LA-NSCLC.
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